Computational medicinal chemistry in fragment-based drug discovery: what, how and when.
暂无分享,去创建一个
Manuel Urbano-Cuadrado | Obdulia Rabal | Julen Oyarzabal | O. Rabal | J. Oyarzábal | Manuel Urbano-Cuadrado | Obdulia Rabal
[1] O. Rabal,et al. Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach. , 2010, Journal of medicinal chemistry.
[2] Robert Kiss,et al. Virtual Fragment Docking by Glide: a Validation Study on 190 Protein-Fragment Complexes , 2010, J. Chem. Inf. Model..
[3] Gerhard Klebe,et al. Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry. , 2010, Journal of molecular biology.
[4] Roman A Laskowski,et al. Chemical fragments that hydrogen bond to Asp, Glu, Arg, and His side chains in protein binding sites. , 2010, Journal of medicinal chemistry.
[5] A. Cavalli,et al. Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition , 2010, Proceedings of the National Academy of Sciences.
[6] Tingjun Hou,et al. Drug and Drug Candidate Building Block Analysis , 2010, J. Chem. Inf. Model..
[7] Aurélien Grosdidier,et al. Rational design of indoleamine 2,3-dioxygenase inhibitors. , 2010, Journal of medicinal chemistry.
[8] Julen Oyarzabal,et al. Optimizing the Performance of In Silico ADMET General Models According to Local Requirements: MARS Approach. Solubility Estimations As Case Study , 2009, J. Chem. Inf. Model..
[9] M. Clark,et al. Fragment-Based Prediction of the Clinical Occurrence of Long QT Syndrome and Torsade de Pointes , 2009, J. Chem. Inf. Model..
[10] Y. Shaul,et al. The nanny model for IDPs. , 2009, Nature chemical biology.
[11] L. Kay,et al. NMR spectroscopy brings invisible protein states into focus. , 2009, Nature chemical biology.
[12] R. Nussinov,et al. The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.
[13] Ian A. Watson,et al. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. , 2009, Journal of medicinal chemistry.
[14] Anna Vulpetti,et al. Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine. , 2009, Journal of the American Chemical Society.
[15] Amedeo Caflisch,et al. Discovery of Plasmepsin Inhibitors by Fragment‐Based Docking and Consensus Scoring , 2009, ChemMedChem.
[16] J. Bajorath,et al. Methods for Computer‐Aided Chemical Biology. Part 5: Rationalizing the Selectivity of Cathepsin Inhibitors on the Basis of Molecular Fragments and Topological Feature Distributions , 2009, Chemical biology & drug design.
[17] Paolo Carnevali,et al. Fragment-Based Computation of Binding Free Energies by Systematic Sampling , 2009, J. Chem. Inf. Model..
[18] Eugen Lounkine,et al. Fragment Formal Concept Analysis Accurately Classifies Compounds with Closely Related Biological Activities , 2009, ChemMedChem.
[19] Kuo-Chen Chou,et al. Investigation into adamantane-based M2 inhibitors with FB-QSAR. , 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).
[20] Gerhard Müller,et al. Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology , 2009, J. Comput. Aided Mol. Des..
[21] Mark Whittaker,et al. The multiple roles of computational chemistry in fragment-based drug design , 2009, J. Comput. Aided Mol. Des..
[22] Ian H. Gilbert,et al. One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening , 2009, Journal of medicinal chemistry.
[23] Lorenz C. Blum,et al. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. , 2009, Journal of the American Chemical Society.
[24] Hongming Wang,et al. Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide , 2009, J. Comput. Aided Mol. Des..
[25] Roderick E. Hubbard,et al. Lessons for fragment library design: analysis of output from multiple screening campaigns , 2009, J. Comput. Aided Mol. Des..
[26] Matthew Paul Gleeson,et al. QM/MM As a Tool in Fragment Based Drug Discovery. A Cross-Docking, Rescoring Study of Kinase Inhibitors , 2009, J. Chem. Inf. Model..
[27] Stefan Senger,et al. Using Tversky Similarity Searches for Core Hopping: Finding the Needles in the Haystack , 2009, J. Chem. Inf. Model..
[28] Michael Devereux,et al. Quantum Isostere Database: A Web-Based Tool Using Quantum Chemical Topology To Predict Bioisosteric Replacements for Drug Design , 2009, J. Chem. Inf. Model..
[29] Woody Sherman,et al. Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation , 2009, J. Comput. Aided Mol. Des..
[30] M. Pellecchia. Fragment-based drug discovery takes a virtual turn. , 2009, Nature chemical biology.
[31] Somesh D. Sharma,et al. Managing protein flexibility in docking and its applications. , 2009, Drug discovery today.
[32] Daniel P. Vercauteren,et al. Fragment-based prediction of cytochromes P450 2D6 and 1A2 inhibition by recursive partitioning , 2009, SAR and QSAR in environmental research.
[33] Susumu Goto,et al. Extraction and Analysis of Chemical Modification Patterns in Drug Development , 2009, J. Chem. Inf. Model..
[34] B. Shoichet,et al. Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.
[35] Julen Oyarzabal,et al. Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists. , 2009, Journal of medicinal chemistry.
[36] Niklas Blomberg,et al. Design of compound libraries for fragment screening , 2009, J. Comput. Aided Mol. Des..
[37] Ismael Zamora,et al. SHOP: Receptor-Based Scaffold HOPping by GRID-Based Similarity Searches , 2009, J. Chem. Inf. Model..
[38] A. Andricopulo,et al. Fragment-Based QSAR and Molecular Modeling Studies on a Series of Discodermolide Analogs as Microtubule-Stabilizing Anticancer Agents , 2009 .
[39] Hanna Geppert,et al. Methods for Computer‐Aided Chemical Biology. Part 4: Selectivity Searching for Ion Channel Ligands and Mapping of Molecular Fragments as Selectivity Markers , 2009, Chemical biology & drug design.
[40] Dima Kozakov,et al. Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..
[41] T. Poulos,et al. Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. , 2009, Journal of medicinal chemistry.
[42] Adriaan P. IJzerman,et al. Substructure Mining of GPCR Ligands Reveals Activity-Class Specific Functional Groups in an Unbiased Manner , 2009, J. Chem. Inf. Model..
[43] Adriano D. Andricopulo,et al. Fragment-based QSAR: perspectives in drug design , 2009, Molecular Diversity.
[44] K. Chou,et al. Fragment‐based quantitative structure–activity relationship (FB‐QSAR) for fragment‐based drug design , 2009, J. Comput. Chem..
[45] Paul Labute,et al. Detection and assignment of common scaffolds in project databases of lead molecules. , 2009, Journal of medicinal chemistry.
[46] Holger Claussen,et al. Searching Fragment Spaces with Feature Trees , 2009, J. Chem. Inf. Model..
[47] Bainan Wu,et al. Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors. , 2008, Journal of medicinal chemistry.
[48] Philip Prathipati,et al. Global Bayesian Models for the Prioritization of Antitubercular Agents , 2008, J. Chem. Inf. Model..
[49] Peter Willett,et al. Assessment of additive/nonadditive effects in structure-activity relationships: implications for iterative drug design. , 2008, Journal of medicinal chemistry.
[50] Luca Sartori,et al. Identification and Selection of "Privileged Fragments" Suitable for Primary Screening , 2008, J. Chem. Inf. Model..
[51] Brian B. Masek,et al. Virtual Screening for R-Groups, including Predicted pIC50 Contributions, within Large Structural Databases, Using Topomer CoMFA , 2008, J. Chem. Inf. Model..
[52] Matthias Rarey,et al. On the Art of Compiling and Using 'Drug‐Like' Chemical Fragment Spaces , 2008, ChemMedChem.
[53] Wayne Vaccaro,et al. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects. , 2008, Journal of medicinal chemistry.
[54] Claudio N. Cavasotto and Narender Singh. Docking and High Throughput Docking: Successes and the Challenge of Protein Flexibility , 2008 .
[55] Hualin Xi,et al. Predicting Kinase Selectivity Profiles Using Free-Wilson QSAR Analysis , 2008, J. Chem. Inf. Model..
[56] Arup K. Ghose,et al. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. , 2008, Journal of medicinal chemistry.
[57] Eugen Lounkine,et al. Formal concept analysis for the identification of molecular fragment combinations specific for active and highly potent compounds. , 2008, Journal of medicinal chemistry.
[58] Paul G Wyatt,et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.
[59] K. Tam,et al. High throughput solubility determination with application to selection of compounds for fragment screening. , 2008, Bioorganic & medicinal chemistry.
[60] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[61] Ian A. Watson,et al. Chemical fragments as foundations for understanding target space and activity prediction. , 2008, Journal of medicinal chemistry.
[62] Christian Lemmen,et al. Similarity searching and scaffold hopping in synthetically accessible combinatorial chemistry spaces. , 2008, Journal of medicinal chemistry.
[63] Maulik R. Patel,et al. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors. , 2008, Bioorganic & medicinal chemistry.
[64] T. Poulos,et al. Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. , 2008, Journal of the American Chemical Society.
[65] Karl Edman,et al. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. , 2008, Journal of medicinal chemistry.
[66] M. Murcko,et al. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. , 2008, Journal of medicinal chemistry.
[67] Hiroaki Wakabayashi,et al. Predicting Key Example Compounds in Competitors' Patent Applications Using Structural Information Alone , 2008, J. Chem. Inf. Model..
[68] Scott Boyer,et al. Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models , 2007, J. Comput. Aided Mol. Des..
[69] Michel Petitjean,et al. MolDiA: A Novel Molecular Diversity Analysis Tool, 1. Principles and Architecture , 2007, J. Chem. Inf. Model..
[70] Glyn Williams,et al. Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.
[71] Jianfeng Pei,et al. A Large Descriptor Set and a Probabilistic Kernel-Based Classifier Significantly Improve Druglikeness Classification , 2007, J. Chem. Inf. Model..
[72] Roderick E Hubbard,et al. The SeeDs approach: integrating fragments into drug discovery. , 2007, Current topics in medicinal chemistry.
[73] Alexander A Alex,et al. Fragment-based drug discovery: what has it achieved so far? , 2007, Current topics in medicinal chemistry.
[74] N. Blomberg,et al. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.
[75] Jean M. Severin,et al. Discovery and Design of Novel HSP90 Inhibitors Using Multiple Fragment‐based Design Strategies , 2007, Chemical biology & drug design.
[76] V. Helms,et al. Transient pockets on protein surfaces involved in protein-protein interaction. , 2007, Journal of medicinal chemistry.
[77] Jonas Boström,et al. Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. , 2007, Bioorganic & medicinal chemistry.
[78] Gergely M Makara,et al. On sampling of fragment space. , 2007, Journal of medicinal chemistry.
[79] Anna Linusson,et al. SHOP: scaffold HOPping by GRID-based similarity searches. , 2007, Journal of medicinal chemistry.
[80] J. Kuneš,et al. The Oriented Development of Antituberculotics (Part II): Halogenated 3‐(4‐Alkylphenyl)‐1,3‐benzoxazine‐2,4‐(3H)‐diones , 2007, Archiv der Pharmazie.
[81] P. Vasanthanathan,et al. QSAR study on pyridinone derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitor: a mixed approach. , 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).
[82] Marcel L Verdonk,et al. Identification of inhibitors of protein kinase B using fragment-based lead discovery. , 2007, Journal of medicinal chemistry.
[83] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[84] K. Wanner,et al. Methods and Principles in Medicinal Chemistry , 2007 .
[85] Harald Mauser,et al. Chemical Fragment Spaces for de novo Design , 2007, J. Chem. Inf. Model..
[86] Santosh A. Khedkar,et al. Encoding Type and Position in Peptide QSAR: Application to Peptides Binding to Class I MHC Molecule HLA-A*0201 , 2007 .
[87] Robert J. Jilek,et al. AllChem: generating and searching 1020 synthetically accessible structures , 2007, J. Comput. Aided Mol. Des..
[88] R. J. Doerksen,et al. Probing the physicochemical and structural requirements for glycogen synthase kinase-3alpha inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides. , 2006, Bioorganic & medicinal chemistry.
[89] Petra Schneider,et al. Scaffold-Hopping: How Far Can You Jump , 2006 .
[90] P. Hajduk,et al. Puzzling through fragment-based drug design , 2006, Nature chemical biology.
[91] W. Jencks,et al. Binding energy, specificity, and enzymic catalysis: the circe effect. , 2006, Advances in enzymology and related areas of molecular biology.
[92] A. Caflisch,et al. Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking. , 2006, Journal of medicinal chemistry.
[93] Kerim Babaoglu,et al. Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.
[94] Stefan Schmitt,et al. Do structurally similar ligands bind in a similar fashion? , 2006, Journal of medicinal chemistry.
[95] C. E. Peishoff,et al. A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.
[96] Matthew P. Repasky,et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.
[97] Christopher W. Murray,et al. Entropic Consequences of Linking Ligands , 2006 .
[98] Harren Jhoti,et al. Pyramid: An Integrated Platform for Fragment‐based Drug Discovery , 2006 .
[99] P. Hajduk,et al. SAR by NMR: An Analysis of Potency Gains Realized Through Fragment‐linking and Fragment‐elaboration Strategies for Lead Generation , 2006 .
[100] Andrew R Leach,et al. Fragment screening: an introduction. , 2006, Molecular bioSystems.
[101] Mark Whittaker,et al. Fragment screening by biochemical assay , 2006, Expert opinion on drug discovery.
[102] Jürgen Bajorath,et al. Assessment of Molecular Similarity from the Analysis of Randomly Generated Structural Fragment Populations , 2006, J. Chem. Inf. Model..
[103] M. Pawłowski,et al. Arylpiperazines with N-acylated amino acids as 5-HT1A receptor ligands. , 2006, Bioorganic & medicinal chemistry letters.
[104] D. V. Von Hoff,et al. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach , 2006, Molecular Cancer Therapeutics.
[105] S. G. Kaskhedikar,et al. Exploring Structural Requirements for Aldose‐Reductase Inhibition by 2,4‐Dioxo‐5‐(naphth‐2‐ylmethylene)‐3‐thiazolidinyl Acetic Acids and 2‐Thioxo Analogues: Fujita‐Ban and Hansch Approach , 2006, Archiv der Pharmazie.
[106] Sandor Vajda,et al. Characterization of protein-ligand interaction sites using experimental and computational methods. , 2006, Current opinion in drug discovery & development.
[107] J. Chmielewski,et al. Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors. , 2006, Chemistry & biology.
[108] A. Caflisch,et al. In Silico Discovery of β-Secretase Inhibitors , 2006 .
[109] Meir Glick,et al. Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..
[110] Paul J Edwards,et al. The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[111] Anthony Williams,et al. Generation and Selection of Novel Estrogen Receptor Ligands Using the De Novo Structure-Based Design Tool, SkelGen , 2006, J. Chem. Inf. Model..
[112] Christian Rummey,et al. In silico fragment-based discovery of DPP-IV S1 pocket binders. , 2006, Bioorganic & medicinal chemistry letters.
[113] Michael Wiese,et al. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. , 2006, Bioorganic & medicinal chemistry.
[114] Dora M Schnur,et al. Are target-family-privileged substructures truly privileged? , 2006, Journal of medicinal chemistry.
[115] Qiang Zhang,et al. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. , 2006, Journal of medicinal chemistry.
[116] Thomas Bäck,et al. Mining a Chemical Database for Fragment Co-occurrence: Discovery of "Chemical Clichés" , 2006, J. Chem. Inf. Model..
[117] P. Hajduk,et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. , 2006, Journal of medicinal chemistry.
[118] Gianni Chessari,et al. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.
[119] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[120] Edward R Zartler,et al. Fragonomics: fragment-based drug discovery. , 2005, Current opinion in chemical biology.
[121] Edgar Jacoby,et al. Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.
[122] Yoshihisa Suzuki,et al. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. , 2005, Journal of molecular biology.
[123] J. T. Metz,et al. Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.
[124] Jun Li,et al. Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase* , 2005, Journal of Biological Chemistry.
[125] Stephan C. Schürer,et al. Prospective Exploration of Synthetically Feasible, Medicinally Relevant Chemical Space , 2005, J. Chem. Inf. Model..
[126] Riccardo Leardi,et al. Nature-Inspired Methods in Chemometrics: Genetic Algorithms and Artificial Neural Networks , 2005 .
[127] Kam Y. J. Zhang,et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.
[128] Christopher W Murray,et al. Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.
[129] Matthew Clark,et al. Generalized Fragment-Substructure Based Property Prediction Method , 2005, J. Chem. Inf. Model..
[130] Robert J. Jilek,et al. "Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities. , 2004, Journal of medicinal chemistry.
[131] Brian Dymock,et al. Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets , 2004, J. Chem. Inf. Model..
[132] Deepa V. Pednekar,et al. STUDIES ON NOVEL NON-IMIDAZOLE HUMAN H4 RECEPTOR ANTAGONISTS USING GFA AND FREE-WILSON ANALYSIS , 2004, Medicinal Chemistry Research.
[133] Robert J. Jilek,et al. Topomers: A Validated Protocol for Their Self-Consistent Generation , 2004, J. Chem. Inf. Model..
[134] T. O'Brien,et al. Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.
[135] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[136] D. Fattori,et al. Molecular recognition: the fragment approach in lead generation. , 2004, Drug discovery today.
[137] Chris L. Waller,et al. A Comparative QSAR Study Using CoMFA, HQSAR, and FRED/SKEYS Paradigms for Estrogen Receptor Binding Affinities of Structurally Diverse Compounds , 2004, J. Chem. Inf. Model..
[138] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[139] S. Teague. Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.
[140] A. Gołębiowski,et al. Lead compounds discovered from libraries: part 2. , 2003, Current opinion in chemical biology.
[141] Robert P. Sheridan,et al. Finding Multiactivity Substructures by Mining Databases of Drug-Like Compounds , 2003, J. Chem. Inf. Comput. Sci..
[142] Peter Willett,et al. Scaffold Searching: Automated Identification of Similar Ring Systems for the Design of Combinatorial Libraries , 2002 .
[143] Marcel L. Verdonk,et al. The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..
[144] James B. Hendrickson,et al. Generating Benign Alternative Syntheses: The SynGen Program , 2002 .
[145] Andrzej M. Brzozowski,et al. Interaction of Transcriptional Intermediary Factor 2 Nuclear Receptor Box Peptides with the Coactivator Binding Site of Estrogen Receptor α* , 2002, The Journal of Biological Chemistry.
[146] D. Bentrem,et al. Structure-Function Relationships of the Raloxifene-Estrogen Receptor-α Complex for Regulating Transforming Growth Factor-α Expression in Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.
[147] C. F. Shen,et al. Testing non-additivity of biological activity in a combinatorial library. , 2002, Combinatorial chemistry & high throughput screening.
[148] Robert P. Sheridan,et al. The Most Common Chemical Replacements in Drug-Like Compounds , 2002, J. Chem. Inf. Comput. Sci..
[149] Matthias Rarey,et al. Similarity searching in large combinatorial chemistry spaces , 2001, J. Comput. Aided Mol. Des..
[150] A Golebiowski,et al. Lead compounds discovered from libraries. , 2001, Current opinion in chemical biology.
[151] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[152] A. Bitonti,et al. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. , 2001, Journal of medicinal chemistry.
[153] Jean M. Severin,et al. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. , 2000, Journal of medicinal chemistry.
[154] A. Petrauskas,et al. ACD/Log P method description , 2000 .
[155] Jun Xu,et al. Drug-like Index: A New Approach To Measure Drug-like Compounds and Their Diversity , 2000, J. Chem. Inf. Comput. Sci..
[156] A H Calvert,et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. , 2000, Journal of medicinal chemistry.
[157] G. Albers,et al. Eyes Wide Open , 2000 .
[158] D. Kostrewa,et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.
[159] R C Wade,et al. Nuclear receptor-DNA binding specificity: A COMBINE and Free-Wilson QSAR analysis. , 2000, Journal of medicinal chemistry.
[160] R. Cramer,et al. Toward general methods of targeted library design: topomer shape similarity searching with diverse structures as queries. , 2000, Journal of medicinal chemistry.
[161] G. Bemis,et al. Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.
[162] Schmid,et al. "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.
[163] Ajay,et al. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.
[164] K. Schaper,et al. FREE-WILSON-TYPE ANALYSIS OF NON-ADDITIVE SUBSTITUENT EFFECTS ON THPB DOPAMINE RECEPTOR AFFINITY USING ARTIFICIAL NEURAL NETWORKS , 1999 .
[165] R. Cramer,et al. Prospective identification of biologically active structures by topomer shape similarity searching. , 1999, Journal of medicinal chemistry.
[166] P. Hajduk,et al. High-throughput nuclear magnetic resonance-based screening. , 1999, Journal of medicinal chemistry.
[167] John W. Erickson,et al. Conformational switching in an aspartic proteinase , 1998, Nature Structural Biology.
[168] Matthias Rarey,et al. Feature trees: A new molecular similarity measure based on tree matching , 1998, J. Comput. Aided Mol. Des..
[169] S H Kim,et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.
[170] Robert D. Clark,et al. Virtual Compound Libraries: A New Approach to Decision Making in Molecular Discovery Research , 1998, J. Chem. Inf. Comput. Sci..
[171] R M Stroud,et al. The additivity of substrate fragments in enzyme-ligand binding. , 1998, Structure.
[172] Yu Chen,et al. Evaluation of Quantitative Structure-Activity Relationship Methods for Large-Scale Prediction of Chemicals Binding to the Estrogen Receptor , 1998, J. Chem. Inf. Comput. Sci..
[173] Michael M. Hann,et al. RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..
[174] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[175] L. Meijer,et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.
[176] K A Dill,et al. Additivity Principles in Biochemistry* , 1997, The Journal of Biological Chemistry.
[177] C A Marchant,et al. Prediction of rodent carcinogenicity using the DEREK system for 30 chemicals currently being tested by the National Toxicology Program. The DEREK Collaborative Group. , 1996, Environmental health perspectives.
[178] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[179] Johann Gasteiger,et al. Computer‐Assisted Planning of Organic Syntheses: The Second Generation of Programs , 1996 .
[180] L Meijer,et al. Multiple modes of ligand recognition: Crystal structures of cyclin‐dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine , 1995, Proteins.
[181] Kornelia Polyak,et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.
[182] W F van Gunsteren,et al. Decomposition of the free energy of a system in terms of specific interactions. Implications for theoretical and experimental studies. , 1994, Journal of molecular biology.
[183] Shaomeng Wang,et al. Computer Automated log P Calculations Based on an Extended Group Contribution Approach , 1994, J. Chem. Inf. Comput. Sci..
[184] Paul A. Bartlett,et al. CAVEAT: A program to facilitate the design of organic molecules , 1994, J. Comput. Aided Mol. Des..
[185] A. Leo. CALCULATING LOG POCT FROM STRUCTURES , 1993 .
[186] W. G. Richards,et al. Application of Neural Networks: Quantitative Structure-Activity Relationships of the Derivatives of 2,4-Diamino-5-(substituted-benzyl) pyrimidines as DHFR Inhibitors. , 1993 .
[187] S. So,et al. Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors. , 1992, Journal of medicinal chemistry.
[188] T. A. Andrea,et al. Applications of neural networks in quantitative structure-activity relationships of dihydrofolate reductase inhibitors. , 1991, Journal of medicinal chemistry.
[189] D. Sanderson,et al. Computer Prediction of Possible Toxic Action from Chemical Structure; The DEREK System , 1991, Human & experimental toxicology.
[190] Arup K. Ghose,et al. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..
[191] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.
[192] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[193] V. E. Golender,et al. Structure-activity relationship oriented languages for chemical structure representation , 1982, J. Chem. Inf. Comput. Sci..
[194] W. Jencks,et al. On the attribution and additivity of binding energies. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[195] Peter C. Jurs,et al. Computer-Assisted Computation of Partition Coefficients from Molecular Structures Using Fragment Constants , 1979, J. Chem. Inf. Comput. Sci..
[196] H. Rappaport. Evaluation of group contributions to ligand binding. , 1979, Journal of theoretical biology.
[197] L. Hodes,et al. A statistical-heuristic methods for automated selection of drugs for screening. , 1977, Journal of medicinal chemistry.
[198] Peter C. Jurs,et al. Generation of Descriptors from Molecular Structures , 1976, J. Chem. Inf. Comput. Sci..
[199] Peter C. Jurs,et al. ADAPT: A Computer System for Automated Data Analysis Using Pattern Recognition Techniques , 1976, J. Chem. Inf. Comput. Sci..
[200] C Silipo,et al. Calculation of hydrophobic constant (log P) from pi and f constants. , 1975, Journal of medicinal chemistry.
[201] C E Berkoff,et al. Substructural analysis. A novel approach to the problem of drug design. , 1974, Journal of medicinal chemistry.
[202] A B Glaz,et al. Cybernetic methods of drug design. I. Statement of the problem--the perceptron approach. , 1973, Computers and biomedical research, an international journal.
[203] T. Fujita,et al. Structure-activity study of phenethylamines as substrates of biosynthetic enzymes of sympathetic transmitters. , 1971, Journal of medicinal chemistry.
[204] E J Corey,et al. Computer-assisted design of complex organic syntheses. , 1969, Science.
[205] S. Free,et al. A MATHEMATICAL CONTRIBUTION TO STRUCTURE-ACTIVITY STUDIES. , 1964, Journal of medicinal chemistry.
[206] Peter Kolb,et al. Docking screens: right for the right reasons? , 2009, Current topics in medicinal chemistry.
[207] Sudhir A. Kulkarni,et al. Group‐Based QSAR (G‐QSAR): Mitigating Interpretation Challenges in QSAR , 2009 .
[208] I. Hațieganu,et al. A QSAR Study on Antimicrobial Activity of Some New Sulfonylhydrazinothiazoles , 2008 .
[209] Stefan Wetzel,et al. The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..
[210] Michal Vieth,et al. Drugs in other drugs: a new look at drugs as fragments. , 2007, Drug discovery today.
[211] S. G. Kaskhedikar,et al. Exploring structural feature of aldose-reductase inhibition by 5-[[2-(omega-carboxyalkoxy)aryl]methylene]-4-oxo-2-thioxothiazolidine derivatives employing Fujita-Ban and Hansch approach. , 2007, Chemical & pharmaceutical bulletin.
[212] L. Strekowski,,et al. Fujita-Ban QSAR analysis and CoMFA study of quinoline antagonists of immunostimulatory CpG-oligodeoxynucleotides. , 2007, Bioorganic & medicinal chemistry.
[213] Gilles Marcou,et al. Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..
[214] Jürgen Bajorath,et al. Chemical Database Mining through Entropy-Based Molecular Similarity Assessment of Randomly Generated Structural Fragment Populations , 2007, J. Chem. Inf. Model..
[215] M. Hack,et al. Pyrazole CCK(1) receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity. , 2006, Bioorganic & medicinal chemistry letters.
[216] I. Pajeva,et al. QSAR and 3D QSAR of inhibitors of the epidermal growth factor receptor , 2006 .
[217] Matthew Clark,et al. Grand Canonical Monte Carlo Simulation of Ligand-Protein Binding , 2006, J. Chem. Inf. Model..
[218] Matthew Clark,et al. Development and Evaluation of an in Silico Model for hERG Binding , 2006, J. Chem. Inf. Model..
[219] M. Hack,et al. Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity. , 2006, Bioorganic & medicinal chemistry letters.
[220] Peter Kirkpatrick. Antiviral drugs: Inside the envelope , 2004, Nature Reviews Drug Discovery.
[221] Paul Gillespie,et al. The Hit-to-Lead Process in Drug Discovery , 2004 .
[222] Marjan Vračko,et al. Artificial neural networks in molecular structures—property studies , 2003 .
[223] R. Cramer,et al. Topomer CoMFA: a design methodology for rapid lead optimization. , 2003, Journal of medicinal chemistry.
[224] Ola Engkvist,et al. Prediction of CNS Activity of Compound Libraries Using Substructure Analysis , 2003, J. Chem. Inf. Comput. Sci..
[225] Knut Baumann,et al. An Alignment-Independent Versatile Structure Descriptor for QSAR and QSPR Based on the Distribution of Molecular Features , 2002, J. Chem. Inf. Comput. Sci..
[226] P N Judson,et al. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.
[227] D Szwajkajzer,et al. Molecular and biological constraints on ligand-binding affinity and specificity. , 1997, Biopolymers.
[228] R. Mannhold,et al. Calculation Procedures for Molecular Lipophilicity: a Comparative Study† , 1996 .
[229] F. Burden. Using Artificial Neural Networks to Predict Biological Activity from Simple Molecular Structural Considerations , 1996 .
[230] W. Meylan,et al. Atom/fragment contribution method for estimating octanol-water partition coefficients. , 1995, Journal of pharmaceutical sciences.
[231] Raimund Mannhold,et al. Calculation of Drug Lipophilicity: The Hydrophobic Fragmental Constant Approach , 1992 .
[232] B. Kowalski,et al. Partial least-squares regression: a tutorial , 1986 .
[233] P. Andrews,et al. Functional group contributions to drug-receptor interactions. , 1984, Journal of medicinal chemistry.
[234] A. Leo,et al. Substituent constants for correlation analysis in chemistry and biology , 1979 .
[235] Rf Rekker,et al. THE HYDROPHOBIC FRAGMENTAL CONSTANT; AN EXTENSION TO A 1000 DATA POINT SET , 1979 .
[236] A. H. Lipkus,et al. Structural Diversity of Organic Chemistry. a Scaffold Analysis of the Cas Registry , 2022 .
[237] Universities of Leeds, Sheffield and York , 2022 .